WO2018144514A3 - Polypeptides de fusion de la superfamille du tnf - Google Patents

Polypeptides de fusion de la superfamille du tnf Download PDF

Info

Publication number
WO2018144514A3
WO2018144514A3 PCT/US2018/016100 US2018016100W WO2018144514A3 WO 2018144514 A3 WO2018144514 A3 WO 2018144514A3 US 2018016100 W US2018016100 W US 2018016100W WO 2018144514 A3 WO2018144514 A3 WO 2018144514A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
cancer
treat
engineered
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/016100
Other languages
English (en)
Other versions
WO2018144514A2 (fr
Inventor
Birgit M. Schoeberl
Eric M. Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of WO2018144514A2 publication Critical patent/WO2018144514A2/fr
Publication of WO2018144514A3 publication Critical patent/WO2018144514A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des polypeptides 4-1BBL modifiés et des polypeptides de fusion Fc-4-1BBL, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à 4-1BB (par exemple, le cancer). L'invention concerne de plus des polypeptides CD70 modifiés et des polypeptides de fusion Fc-CD70, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à CD70 (par exemple, le cancer). L'invention concerne en outre des polypeptides GITRL modifiés et des polypeptides de fusion Fc-GITRL, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à GITRL (par exemple, le cancer). L'invention concerne également des polypeptides OX40L modifiés et des polypeptides de fusion Fc-OX40L, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés à OX40L (par exemple, le cancer). L'invention concerne par ailleurs des polypeptides CD40L modifiés et des polypeptides de fusion Fc-CD40L, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés au CD40L (par exemple, le cancer). L'invention concerne de plus encore des polypeptides LIGHT modifiés et des polypeptides de fusion Fc-LIGHT, ainsi que des méthodes d'utilisation de ces polypeptides et de compositions pour traiter des troubles liés au LIGHT (par exemple, le cancer).
PCT/US2018/016100 2017-02-01 2018-01-31 Polypeptides de fusion de la superfamille du tnf Ceased WO2018144514A2 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762453373P 2017-02-01 2017-02-01
US201762453357P 2017-02-01 2017-02-01
US201762453338P 2017-02-01 2017-02-01
US201762453354P 2017-02-01 2017-02-01
US201762453313P 2017-02-01 2017-02-01
US62/453,313 2017-02-01
US62/453,338 2017-02-01
US62/453,373 2017-02-01
US62/453,357 2017-02-01
US62/453,354 2017-02-01

Publications (2)

Publication Number Publication Date
WO2018144514A2 WO2018144514A2 (fr) 2018-08-09
WO2018144514A3 true WO2018144514A3 (fr) 2018-10-04

Family

ID=63041053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/016100 Ceased WO2018144514A2 (fr) 2017-02-01 2018-01-31 Polypeptides de fusion de la superfamille du tnf

Country Status (1)

Country Link
WO (1) WO2018144514A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094574A1 (fr) * 2017-11-09 2019-05-16 Medimmune, Llc Polypeptides de fusion bispécifiques et leurs procédés d'utilisation
WO2021072127A2 (fr) 2019-10-08 2021-04-15 Fred Hutchinson Cancer Research Center Protéines cd70 trimériques génétiquement modifiées et leurs utilisations
MX2022008214A (es) * 2020-01-09 2022-08-08 Hoffmann La Roche Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl.
US20240166720A1 (en) * 2021-03-12 2024-05-23 Janssen Biotech, Inc. Bioengineered immunomodulatory fusion protein compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041181A1 (en) * 2009-01-09 2012-02-16 Oliver Hill Fusion proteins forming trimers
US20160340399A1 (en) * 2015-03-31 2016-11-24 Hoffmann-La Roche Inc. Antigen binding molecules comprising a trimeric tnf family ligand

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041181A1 (en) * 2009-01-09 2012-02-16 Oliver Hill Fusion proteins forming trimers
US20160340399A1 (en) * 2015-03-31 2016-11-24 Hoffmann-La Roche Inc. Antigen binding molecules comprising a trimeric tnf family ligand

Also Published As

Publication number Publication date
WO2018144514A2 (fr) 2018-08-09

Similar Documents

Publication Publication Date Title
PH12017501372A1 (en) Tnfrsf-binding agents and uses thereof
WO2018144514A3 (fr) Polypeptides de fusion de la superfamille du tnf
ZA202211577B (en) Multivalent and multispecific 41bb-binding fusion proteins
MX2018008310A (es) Proteinas de fusion de union a ox40 multivalentes y multiespecificas.
EP3247728A4 (fr) Molécules de liaison aux récepteurs de la superfamille des facteurs de nécrose tumorale (tnf) et leurs utilisations
MX2018000948A (es) Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
WO2017077085A3 (fr) Anticorps immunomodulateurs
PH12017500634A1 (en) Compositions and methods of use for augmented immune response and cancer therapy
PH12016502267A1 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
PE20180330A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
WO2016191643A3 (fr) Agents de liaison à tigit et leurs utilisations
EP4344748A3 (fr) Anticorps anti-gitr et leurs utilisations
WO2019086331A3 (fr) Anticorps bispécifiques se liant à alk-1 et bmpr-2
HK1250044A1 (zh) Gitrl融合蛋白及其用途
GEP20146176B (en) Agonist dr5 binding polypeptides
WO2013184912A3 (fr) Agents liants modulant la voie de signalisation hippo et leurs utilisations
EA201170636A1 (ru) Антагонисты толл-подобного рецептора 3
WO2014105958A3 (fr) Composés pyrimidine fusionnés et leur utilisation
MX2025000992A (es) Anticuerpos anti-cd40 y usos de los mismos
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
NZ763061A (en) Anti-ox40 antibodies and uses thereof
FR3046334B1 (fr) Composition solide pour le relargage controle de substances semiochimiques
EA201171307A1 (ru) Антагонисты толл-подобного рецептора 3
EP3167292A4 (fr) Dosage srm/mrm de la protéine du membre 8 de la superfamille des récepteurs du facteur de nécrose tumorale (cd30)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18747358

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18747358

Country of ref document: EP

Kind code of ref document: A2